Is Ketamine Legal in Vermont? (2026)

Instrument

Definitions: depressant or stimulant drug (ketamine); regulated drug

Source

https://legislature.vermont.gov/statutes/fullchapter/18/084

Retrieved

2026-10-31

Fingerprint

9e2abd843dbe6436

(6) "Depressant or stimulant drug" means:

(A) any drug that contains any quantity of barbituric acid or any of the salts of barbituric
            acid, or any derivative of barbituric acid, that is designated as habit-forming because
            of its effect on the central nervous system in the rules adopted by the Department
            of Health under section 4202 of this title;

(B) any drug, other than methamphetamine, that contains any quantity of amphetamine or
            any of its optical isomers, any salt or amphetamine or any salt of an optical isomer
            of amphetamine, that the Department of Health so designates by such rule as habit-forming
            because of its effect on the central nervous system;

(C) gamma hydroxybutyric acid, including its salts, isomers, or salts of isomers;

(D) gamma butyrolactone, including 4-butyrolactone and gamma hydroxybutyric acid lactone,
            including its salts, isomers, or salts of isomers, when packaged, marketed, manufactured,
            or intended for human consumption;

(E) ketamine, including its salts, isomers, or salts of isomers;

(F) flunitrazepam, including its salts, isomers, or salts of isomers; and

(G) any drug, other than methamphetamine, that contains any quantity of a substance that
            the Department of Health so designates by such rule as having a serious potential
            for abuse arising out of its effect on the central nervous system.

(7) “Dispense” includes distribute, leave with, give away, dispose of, or deliver.

(8) "Exempt officials" includes officials of the United States, insular possessions, territories,
            the District of Columbia, state, and political subdivisions.

(9) “Federal drug laws” means the laws of the United States relating to one or more of
            those drugs which are defined in this chapter as regulated drugs.

(10) "Hallucinogenic drugs" means stramonium, mescaline or peyote, lysergic acid diethylamide,
            and psilocybin, and all synthetic equivalents of chemicals contained in resinous extractives
            of Cannabis sativa, or any salts or derivatives or compounds of any preparations or
            mixtures thereof, and any other substance that is designated as habit-forming or as
            having a serious potential for abuse arising out of its effect on the central nervous
            system or its hallucinogenic effect in the rules adopted by the Department of Health
            under section 4202 of this title.

(11) “Hospital” means an institution for the care and treatment of the sick and injured
            licensed as a hospital under chapter 43 of this title and a hospital conducted, maintained,
            and operated by the United States or the State of Vermont, approved under this chapter
            as proper to be entrusted with the custody and use of regulated drugs under the direction
            of a physician or dentist, confirmed by an official written order signed by a person
            authorized to prescribe such drugs.

(12) "Laboratory" means a laboratory approved under this chapter as proper to be entrusted
            with the custody and use of regulated drugs for scientific and medical purposes and
            for purposes of instruction.

(13) “License” means a license to practice their profession issued to one of those persons
            listed in subdivisions (1)(A) through (F) of this section by the person’s respective
            professional board under the applicable laws of this State, or a license issued by
            the Department of Health under section 4206 of this title to a person not subject to the jurisdiction of any such professional board.

(14) "Manufacturer" means a person authorized by law to manufacture, bottle, or pack drugs
            in this State and who has a license issued to the person under this chapter to compound,
            mix, cultivate, produce, or prepare regulated drugs, but does not include a pharmacy
            that compounds such drugs to be sold or dispensed on prescriptions at retail.

(15)(A) “Cannabis” means all parts of the plant Cannabis sativa L., except as provided by
            subdivision (B) of this subdivision (15), whether growing or harvested, and includes:

(i) the seeds of the plant;

(ii) the resin extracted from any part of the plant; and

(iii) any compound, manufacture, salt, derivative, mixture, or preparation of the plant,
            its seeds, or resin.

(B) “Cannabis” does not include:

(i) the mature stalks of the plant and fiber produced from the stalks;

(ii) oil or cake made from the seeds of the plant;

(iii) any compound, manufacture, salt, derivative, mixture, or preparation of the mature
            stalks, fiber, oil, or cake;

(iv) the sterilized seed of the plant that is incapable of germination; or

(v) hemp or hemp products, as defined in 7 V.S.A. § 852.

(16) “Narcotic,” “narcotics,” or "narcotic drugs" means opium, coca leaves, pethidine (isonipecaine,
            meperidine), and opiates or their compound, manufacture, salt, alkaloid, or derivative,
            and every substance neither chemically nor physically distinguishable from them, and
            preparations containing such drugs or their derivatives, by whatever trade name identified
            and whether produced directly or indirectly by extraction from substances of vegetable
            origin, or independently by means of chemical synthesis or by a combination of extraction
            and chemical synthesis, as the same are so designated in the rules adopted by the
            Department of Health under section 4202 of this title.

(17) “Nurse” means any person authorized by law to practice nursing in this State.

(18) “Nursing home” means a facility, other than a hospital, operated for the purpose of
            providing lodging, board, and nursing care to persons who are sick, have an infirmity
            or disability, or are convalescing, approved under this chapter as proper to be entrusted
            with the custody and use of regulated drugs prescribed for such individual patients
            under its care under the direction of a physician or dentist, confirmed by an official
            written order signed by a person authorized to prescribe such drugs. No nursing home
            shall be granted a certificate of approval for the possession and use of such drugs
            unless such nursing home has a registered nurse or a licensed practical nurse on duty
            or on call 24 hours daily who will have sole responsibility for those drugs. Nothing
            in this chapter shall be construed as conferring on any nursing home, convalescent
            home, or home for the aged any authority, right, or privilege beyond that granted
            to it by the law under which it is licensed or otherwise authorized to function.

(19) “Official written order” means an order written on a form prescribed for that purpose
            by the U.S. Commissioner of Narcotics and issued by the U.S. Commissioner of Internal
            Revenue, under any laws of the United States making provision therefor, if such order
            forms are authorized and required by federal law, and if no such order form is provided,
            then on an official form provided for that purpose by the Commissioner of Health.

(20) "Person" includes an individual, partnership, corporation, association, trust, or
            other institution or entity.

(21) “Pharmacist” means any person authorized by law to practice pharmacy in this State;
            but nothing in this chapter shall be construed as conferring on a person any authority,
            right, or privilege that is not granted to him or her by the pharmacy laws of his
            or her state.

(22) “Pharmacy” means any place registered as such by the Board of Pharmacy in which drugs,
            prescriptions, or poisons are possessed for the purpose of compounding, dispensing,
            or retailing, or in which drugs, prescriptions, or poisons are compounded, dispensed,
            or retailed, or in which such drugs, prescriptions, or poisons are by advertising
            or otherwise offered for sale at retail and which has a license issued to it under
            this chapter authorizing the retail dealing of regulated drugs.

(23) “Physician” means a person authorized by law to practice medicine in this State and
            who has a license issued to the person under this chapter authorizing him or her to
            use regulated drugs in connection with his or her professional practice.

(24) “Practitioner” includes a physician, dentist, veterinarian, surgeon, or any other
            person who may be lawfully entitled under this chapter to distribute, dispense, prescribe,
            or administer regulated drugs to patients.

(25) "Prescribe" means an order for a patient made or given by a practitioner.

(26) "Prescription" means an order for a regulated drug made by a physician, physician
            assistant, advanced practice registered nurse, dentist, or veterinarian licensed under
            this chapter to prescribe such a drug which shall be in writing except as otherwise
            specified in this subdivision. Prescriptions for such drugs shall be made to the order
            of an individual patient, dated as of the day of issue and signed by the prescriber.
            The prescription shall bear the full name, address, and date of birth of the patient,
            or if the patient is an animal, the name and address of the owner of the animal and
            the species of the animal. Such prescription shall also bear the full name, address,
            and registry number of the prescriber and, unless electronically prescribed, shall
            be written with ink, indelible pencil, or typewriter; if typewritten, it shall be
            signed by the prescriber. A written or typewritten prescription for a controlled substance,
            as defined in 21 C.F.R. Part 1308, shall contain the quantity of the drug written both in numeric and word form. If
            a prescription is communicated orally, it shall be reduced promptly to writing by
            the pharmacist. Nothing in this subdivision is meant to authorize the oral communication
            of a prescription when a written prescription is otherwise required.

(27) "Registration" means the annual registration of licenses and certificates under this
            chapter.

(28) "Registry number" means the number assigned under rules adopted by the Department
            of Health to each person authorized under this chapter to use, prescribe, dispense,
            possess, or administer a regulated drug in connection with his or her professional
            practice.

(29) "Regulated drug" means:

(A) a narcotic drug;

(B) a depressant or stimulant drug, other than methamphetamine;

(C) a hallucinogenic drug;

(D) Ecstasy;

(E) cannabis;

(F) methamphetamine; or

(G) xylazine.

Instrument

Regulated Drug Rule, Section 7.0, hallucinogenic substances

Source

https://www.healthvermont.gov/sites/default/files/documents/pdf/REG_regulated-drugs.pdf

Retrieved

2026-10-28

Fingerprint

444edde14dc93117

7.0  Hallucinogenic Drugs; Synthetic Cannabinoids; Tryptamines; Cannabinimimetics;

Mescaline Analogs; Dissociatives; Trade or Chemical Name

•  1-(1-Phenylcyclohexyl)pyrrolidine; PCPy; Rolicyclidine

•  1-[1-(2-Thienyl)cyclohexyl]piperidine; TCP; Tenocyclidine

•  1-[1-(2-Thienyl)cyclohexyl]pyrrolidine; TCPy

•  1-Piperidinocyclohexanecarbonitrile; PCC

•  2-Fluorodeschloroketamine; 2-Fl-2'-Oxo-PCM; Fluoroketamine; 2-FDCK

•  2-Trifluoromethyldeschloroketamine; 2-TFMDCK; TFM-K

•  5F-APICA; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide

•  5F-PCN; 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3-

carboxamide

Page 17 of 33

Effective Date:7/15/2017

•  AB-FUBINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-

indazole-3-carboxamide

•  AB FUBINACA; 2-fluorobenzyl isomer

•  ADB-CHMINACA

•  ADB-PINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-

carboxamide

•  bromo-dragonfly; 1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine

•  CUMYL  BICA

•  CUMYL-5F-PICA

•  CUMYL-5F-PINACA

•  CUMYL-PICA

•  CUMYL-PINACA

•  CUMYL-THPINACA

•  delta-9-tetrahydrocannabinol

•  FUB-AMB

•  MAB-CHMINACA; N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-

1H-indazole-3-carboxamide

•  Nabilone

•  NM-2201

•  Parahexyl

•  PX-1

•  PX-2

Page 18 of 33

Effective Date:7/15/2017

•  N-Ethyl-3-piperidyl benzilate

•  1-(4-methoxybenzoyl)-4-methylpiperazine;MEXP;Methoxypiperamide

•  2,5-dimethoxyamphetamine; 2,5-dimethoxy-a-methylphenethylamin 2,5 DMA

•  2-MeO-ketamine; methoxyketamine

•  2C-B; 4-bromo-2,5-dimethoxy-benzeneethanamine, monohydrochloride

•  2C-C; 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine

•  2C-D; 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine

•  2C-E; 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine

•  2C-H; 2-(2,5-Dimethoxyphenyl)ethanamine

•  2C-I; 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine

•  2C-N; 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine

•  2C-P; 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine

•  2C-T-2; 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine

•  2C-T-4; 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine

•  2C-T-7; 2,5-dimethoxy-4-(propylthio)-benzeneethanamine, monohydrochloride

•  2C-TFM-NBOMe; 2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-

methoxyphenyl)methyl]ethanamine

•  2CBCB-NBOMe; N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-
dimethoxybicyclo[4.2.0]octa- 1,3,5-trien-7-yl]methanamine

•  2CBFly-NBOMe; N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-

b’]difuran-4-yl)-2-aminoethane

•  3,4,5-trimethoxy amphetamine

•  3,4-methylenedioxy amphetamine

Page 19 of 33

Effective Date:7/15/2017

•  3-HO-PCE; 3-[1-(ethylamino)cyclohexyl]phenol

•  3-HO-PCP

•  3-Methoxyphencyclidine; 3-MeO-PCP; 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine

•  4-AcO-DET; 3-(2-Diethylaminoethyl)-1H-indol-4-yl acetate

•  4-AcO-DMT; 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl acetate

•  4-AcO-DPT

•  4-AcO-MET; 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl acetate

•  4-bromo-2, 5-dimethoxyamphetamine; DOB; bromo-DMA

•  4-HO-MET; 3-(2-(ethyl(methyl)amino)ethyl)-1H-indol-4-ol

•  4-HO-MIPT; 3-(2-[Isopropyl(methyl)amino]ethyl)-1H-indol-4-ol; 4-hydroxy-MIPT

•  4-HO-MPMI; (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole

•  4-HO-MPT; 3-{2-[methyl(propyl)amino]ethyl}-1H-indol-4-ol

•  4-MeO-AET

•  4-MeO-MIPT

•  4-MeO-PCP; 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine; 4-Methoxyphencyclidine

(methoxydine)

•  4-methoxyamphetamine; 4-methoxy-a-methylphenethylamine paramethoxyamphetamine:

PMA

•  4-methyl-2, 5-dimethoxyamphetamine; 4-methyl-2, 5-dimethoxy-a-ethylphenethylamine;

“DOM”; and “STP.”

•  4-methyl-AET

•  5-APB; 5-(2-aminopropyl)benzofuran

•  5-EAPB; 5-(2-Ethylaminopropyl)Benzofuran

Page 20 of 33

Effective Date:7/15/2017

•  5F-AMB; 5-fluoro AMP

•  5F-ADBICA; 5-fluoro ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-

fluoropentyl)-1H-indole-3-carboxamide

•  5F-AKB48; AKB48 N-(5-fluoropentyl) analog; 5f-APINACA; APINACA 5-fluoropentyl
analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide

•  5F-MN-018;5-fluoro MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide

•  5F-MN24; 5-fluoro NNEI; 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-

carboxamide

•  5F-SDB-005; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate

•  5F-THJ-2201;  (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone

•  5FAB-FUBINACA

•  5FAB-PINACA; AB-PINACA 5 fluoro analog; (S)-N-(1-amino-3-methyl-1-oxobutan-2-

yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide

•  5FPB22;  5-fluoro PB-22; 5-fluoro QUPIC; 1-(5-fluoropentyl)-8-quinolinyl ester-1H-

indole-3-carboxylic acid

•  5FSDB-006; 5-fluoro SDB-006; N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide

•  5-IT; 5-(2-aminopropyl)indole

•  5-MAPB; 5-(2-Methylaminopropyl) Benzofuran

•  5-MeO-AMT; 1-(5-methoxy-1H-indol-3-yl)propan-2-amine

•  5-MeO-DALT; N-ally1-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine; 5-

MED

•  5-MeO-DET; N,N-Dethyl-5-Methoxytryptamine

•  5-MeO-DIPT; 3-[2-(Diisopropylamino)ethyl]-5-methoxyindole

•  5-MeO-DMT; 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine

•  5-MeO-DPT; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine

Page 21 of 33

Effective Date:7/15/2017

•  5-MeO-MDA; 5-methoxy-3, 4-methylenedioxy amphetamine

•  5-MeO-MIPT; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine

•  5-methoxy-3,4-methylenedioxy amphetamine

•  5-MeO-MPMI; (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole

•  5F-UR-144; (5-fluoropentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone;

XLR11

•  6-APB; 6-(2-aminopropyl)benzofuran

•  7-hydroxymitragynine; (αE,2S,3S,7aS,12bS)-3-Ethyl-1,2,3,4,6,7,7a,12b-octahydro-7a-

hydroxy-8-methoxy-α-(methoxymethylene)indolo[2,3-a]quinolizine-2-acetic acid methyl
ester

•  25B-NBOMe; NBOMe-2C-B; BOM 2-CB; Cimbi-36; 2-(4-bromo-2,5-dimethoxyphenyl)-

N- [(2-methoxyphenyl)methyl]ethanamine

•  25C-NBOMe ; 2C-C-NBOMe; NBOMe-2C-C; Cimbi-82; 2-(4-chloro-2,5-

dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

•  25I-NBF; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethanamine

•  25I-NBMD; NBMD-2C-I; Cimbi-29; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-

methylenedioxyphenyl)methyl]ethanamine

•  25I-NBOH; 2-((2-(4-iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol

•  25I-NBOMe; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

•  A1 dodeca-2E, 4E, 8Z, 10Z – tetraenoic acid isobutyl amide

•  A2 dodeca-2E, 4E, dienoic acid idobutylamide

•  A796,260; 1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3 tetramethylcyclopropyl)

methanone

•  A-834,735; 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-

tetramethylcyclopropyl)methanone

Page 22 of 33

Effective Date:7/15/2017

•  A-836,339; N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-

tetramethylcyclopropane-1-carboxamide

•  AB-001; 1-pentyl-3-(1-adamantoyl) indole

•  AB-034; [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-

tetramethylcyclopropyl)methanone

•  AB-CHMINACA; N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-

1H-indazole-3-carboxamide

•  AB-PINACA

•  ACEA; N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

•  ACPA; N-cyclopropyl-5Z,8Z,11Z,14Z-eicosatetraenamide

•  ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide

•  AH-7921; 3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide

•  AKB-48; N-adamantyl-1-pentylindazole-3-carboxamide (APINACA)

•  AL-LAD; 6-allyl-6-nor-LSD; 6-Allyl-6-nor-lysergic acid diethylamide

•  AM630; Iodopravadoline; [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-

methoxyphenyl)-methanone

•  AM-679; 1-pentyl-3-(2-iodobenzoyl)indole

•  AM-694; 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; OR 1-[(5-fluoropentyl)-1H-indol-3-

yl]-(2-iodophenyl)methanone

•  AM-1220; (R)-(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)(naphthalen-1-

yl)methanone; OR 1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole; OR 1- [(N-
methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole

•  AM-1241; 1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole

•  AM-1248; 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole

•  AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole

Page 23 of 33

Effective Date:7/15/2017

•  AM-2233; 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole

•  AM-4113

•  AMT; a-methyltryptamine

•  ASDB-FUB-187 BAY 38-7271; (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-

trifluorobutyl-1- sulfonate

•  Bufotenine; 3-(b-dimethylaminoethyl) 5-hydroxyindole; 3-(2-di-methylamineothyl) -5-

indolol;N, N-dimethylserotonin; 5-hydroxy-N-dimethyltryptamine; mappine.

•  CB-13, SAB-378; Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone

•  CP47,497

•  CP 47,497 homologues; Known as the C6, C7, C8 or C9 homologues and also the
dimethylhexyl, dimethylheptyl; dimethyloctyl or dimethylnonyl homologues

•  CP 50,556-1, Levonantradol; 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-

5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; OR [(6S,6aR,9R, 10aR)-9-
hydroxy-6-methyl-3-[(2R)-5-ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-
octahydrophenanthridin-1-yl] acetate; OR [9-hydroxy-6-methyl-3-[5-phenylpentan-2-
yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate

•  CP 55,940; 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-

methyloctan-2-yl)phenol

•  cannabicyclohexanol

•  Cannabimimetic Agents means, collectively, any chemical that is a cannabinoid receptor

type 1 (CB1) or cannabinoid receptor type 2 (CB2) agonist, or any salts, isomers,
derivatives, or analogs of these chemicals.  Structural classes include but are not limited
to: (a) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic
ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.
(b) 3-(1-naphthoyl)indole or 3-(1-naphthyl)indole with substitution at the nitrogen atom of
the indole ring, whether or not further substituted on the indole ring to any extent, whether
or not substituted on the naphthoyl or naphthyl ring to any extent. (c) 3-(1-
naphthoyl)pyrrole with substitution at the nitrogen atom of the pyrrole ring, whether or
not further substituted in the pyrrole ring to any extent, whether or not substituted on the
naphthoyl ring to any extent. (d) 1-(1-naphthylmethyl)indene with substitution of the 3-
position of the indene ring, whether or not further substituted in the indene ring to any
extent, whether or not substituted on the naphthyl ring to any extent.(e) 3-
phenylacetylindole or 3-benzoylindole with substitution at the nitrogen atom of the indole

Page 24 of 33

Effective Date:7/15/2017

ring, whether or not further substituted in the indole ring to any extent, whether or not
substituted on the phenyl ring to any extent. (f) indole- (2,2,3,3-
tetramethylcyclopropyl)methanone, with substitution at the nitrogen atom of the indole
ring, whether or not further substituted in the indole ring to any extent, whether or not
substituted on the phenyl ring to any extent.  (g) N- adamantyl-indole-3-carboxamide,
with substitution at the nitrogen atom of the indole ring, whether or not further substituted
in the indole ring to any extent, whether or not substituted on the phenyl ring to any
extent. (h) (1,3-thiazol-2- ylidine)-2,2,3,3- tetramethylcyclopropane-1-carboxamide, with
substitution to any extent at any position of the thiazolylidine ring.

•  DET; Diethyltryptamine; N, N-Diethyltryptamine

•  DIPT; Diisopropyltryptamine

•  DMT; Dimethyltryptamine

•  DPT; N,N,-dipropyltryptamine

•  Dichloropane, RTI-111, O-401; methyl (1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-8-

azabicyclo[3.2.1]octane-2-carboxylate

•  EAM-2201; JWH-210 N-(5 fluoropentyl) analog; (4-ethyl-1-naphthalenyl)[1-(5-

fluoropentyl)-1H-indol-3-yl]-methanone

•  EG-018; naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone

•  Ethyl-ketamine; 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone

•  FDU-PB-22; naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate

•  FAB-144; (1-(5-fluoropentyl)-1H-indazol-3-yl)(2,2,3,3-

tetramethylcyclopropyl)methanone

•  F-UPB-22

•  FUB-AKB48; AKB48 N-(4-fluorobenzyl) analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(4-

fluorobenzyl)-1H-indazole-3-carboxamide

•  FUB-PB22; FUB-PB-22; quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate

•  FUBIMINA; AM2201 Benzimidazole analog; BIM-2201, FTHJ; (1-(5-fluoropentyl)-1H-

benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone

•  HDMP-28; Methylnaphthidate

Page 25 of 33

Effective Date:7/15/2017

•  HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-

6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol; OR [(6aR,10aR)-9-(hy droxymethyl)- 6,6-
dimethyl-3-(2-methyl octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR 1,1-
Dimethylheptyl-11-hydroxytetrahydrocannabinol

•  HU-211, Dexanabinol; (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-
yl)- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR (6aS, 10aS)-9-(hydroxymethyl)-
6,6-dimethyl- 3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol

•  HU-243; 3-dimethylheptyl-11-hydroxyhexahydrocannabinol; canbisol, nabidrox

•  HU-308; [(91R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-

bicyclo[3.1.1]hept-3-enyl]methanol

•  HU-331; 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-

pentyl- 2,5-cyclohexadiene-1,4-dione

•

Ibogaine; 7-Ethyl-6, 6a,7,8,9,10,12, 3-octahydro-2-methoxy-6, 9-methano-5H-pyrido (1’,
2’: 1,2 azepine 4, 5-b) indole; tab ernanthe iboga

•  JTE-907; N-(benzol[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-

dihydroquinoline-3-carboxamide

•  JWH-007; 1-pentyl-2-methyl-3-(1-naphthoyl)indole

•  JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone; OR 1-propyl-2-
methyl-3-(1-naphthoyl)indole; OR (2-methyl-1-propyl-1H-indol-3-yl)-1- naphthalenyl-
methanone

•  JWH-016; (1-butyl-2-methyl-1H-indol-3-yl)-1-naphthalenyl-methanone)

•  JWH-018; AM-678; Naphthalen-1-yl-(1-pentylindol-3-yl)methanone

•  JWH-019; napthanlen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-hexyl-3-(1-

naphthoyl)indole; OR 1-hexyl-3-(naphthoyl)indole; OR 1-hexyl-3-(naphthalen-1-
oyl)indole

•  JWH-022; 1-naphthalenyl[1-(4-penten-1-yl)-1H-indol-3-yl]-methanone

•  JWH-030; naphthalen-1-yl-(1-pentylpyrrol- 3-yl)methanone

•  JWH-073; naphthalen-1-yl-(1-butylindol-3-yl)methanone

Page 26 of 33

Effective Date:7/15/2017

•  JWH-081; 4-methoxynapthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(4-
methoxy-1-naphthoyl)indole; OR 4-methoxynaphthalen-1-yl-(1-pentylindole-3-yl)
methanone; OR 1-pentyl-3-[1-(4-methoxynaphthoy)]indole

•  JWH-098; 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole; OR 4-
methoxynaphthalen- 1-yl-(1-pentyl-2-methylindol-3-yl)methanone

•  JWH-122; 1-pentyl-3-(4-methyl-1-naphthoyl)indole; OR (4-methyl-1-naphthalenyl)(1-

pentyl-1H-indol-3-yl)-methanone

•  JWH-147; (1-hexyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenyl-methanone

•  JWH-164; 1-pentyl-3-(7-methoxy-1-naphthoyl)indole; OR 7-methoxynaphthalen-1-yl-(1-

pentylindol-3-yl)methanone

•  JWH-167; 1-pentyl-3-(phenylacetyl)indole

•  JWH-175; 3-(napthalen-1-ylmethyl)-1-pentyl-1H-indole; OR 1-Pentyl-1H-indol-3-yl-(1-

naphthyl)methane

•  JWH-176; E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane

•  JWH-184; 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane

•  JWH-199

•  JWH-200; WIN 55,225; (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone

•  JWH-201; 1-pentyl-3-(4-methocyphenylacetyl)indole; OR 1-pentyl-3-(4-

methoxyphenylacetyl)indole

•  JWH-203; 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone; OR 1-pentyl-3-(2-

chlorophenylacetyl)indole

•  JWH-210; 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(4-

ethyl-1- naphthoyl)indole

•  JWH-250; 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; OR 1-pentyl-3-(2-
methoxyphenylacetyl)indole; OR 1-pentyl-3-(methoxyphenylacetyl)indole; OR 1-(1-
pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone

•  JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; OR 1-pentyl-3-(2-

methylphenylacetyl)indole

Page 27 of 33

Effective Date:7/15/2017

•  JWH-302; 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone

•  JWH-307; (5-(2-fluorophenyl)-1-pent ylpyrrol-3-yl)-naphthalen-1-ylmethanone

•  JWH-370; [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone

•  JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole

•  L-759,633; 3-(1,1-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-methoxy-6,6,9-trimethyl-

6H-dibenzo[b,d]pyran

•  L-759,656

•  Lysergic acid

•  Lysergic acid amide

•  Lysergic acid dimethylamide

•  LSZ; Lysergic acid 2,4-dimethylazetidide, Diazedine, Lambda, LA-SS-AzLysergic acid

diethylamide

•  MAM-2201; 4-methyl-1-naphthalenyl(1-fluoropentyl-1H-indol-3-yl)methanone

•  MIPT; N-isopropyl-N-methyltryptamine

•  MA-CHMINICA; AMB N-METHYLCYCLOHEXYL ANALOG, AB-CHMINACA,
MAB-AB-CHMINACA; methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-L-
valinate

•  MDMB-CHMINICA; (S)-MDMB-CHMINACA; N-[[1-(cyclohexylmethyl)-1H-indazol-

3-yl]carbonyl]-3-methyl-L-valine, methyl ester

•  Mepirapim; JWH-018-4(methylpiperazine); (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-

3-yl)methanone, monohydrochloride

•  Mescaline

•  Methoxetamine (MXE); 3-MeO-2-Oxo-PCE; (RS)2-(3-methoxyphenyl)-2-

(ethylamino)cyclohexanone

•  MMB-2201; I-AMB; methyl (1-(5-fluoropentyl)-1H-indole-3-carbonyl)-L-valinate

Page 28 of 33

Effective Date:7/15/2017

•  MMB-CHMINACA; (2S)-methyl-2-(1-(cyclohexylmethyl)-1 H-indol-3-

ylcarbonylamino)-3,3-dimethylbutanoate

•  MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide

•  MN-24; NNEI; N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide; AM-6527

•  Mitragynine

•  N-ethyl-3 piperidyl benzilate

•  N-methyl-3-piperidyl benzilate

•  NM2201

•  Peyote

•  Psilocybin

•  Psilocin; 4-OH-DMT

•  RCS-4, SR-19; [(4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone]; OR 1-pentyl-3-

[(4- methoxy)-benzoyl]indole; OR 1-pentyl-3-(4-methoxybenzoyl)indole; OR (4-
methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone

•  RCS-8, SR-18; 1-(2-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(2-methyoxyphenylethanone);

OR 1-[2-(2-cyclohexylethyl)-1H-indol-3-yl]-2-methoxyphenylethanone; OR 1-(2-
cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole

•  STS-135; N-adamantyl-1-pentylindazole-3-carboxamide

•  Salvia divinorum

•  Salvinorin A, Active ingredient of salvia plant

•  SDB-005; naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate

•  SR 144528; 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-

1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide

•  STS-144; (1-(5-fluoropentyl)-1H-indol-3-yl)(pyridin-3-yl)methanone

Page 29 of 33

Effective Date:7/15/2017

•  Stramonium

•  THJ-018; JWH-018 Indazole analog; 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-

methanone

•  THJ-2201; Fluoropentyl JWH-018 Indazole, AM2201 indazole analog, 5-Fluoro

•  Tetrahydrocannabinols (Since nomenclature of these substances is not internationally

standardized, compounds of these structures, regardless of numeric designation of atomic
position are covered).

•  Thiophene Analog of Phencyclidine; 1-[1-(2-thlenyl) cyclohexyl] piperidine; 2-Thyneyl

Analog of Phencyclidine; TPCP

•  UR-144; (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone

•  URB-597; [3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate

•  URB-602; Cyclohexyl [1,1’-biphenyl]-3-ylcarbamate

•  URB-754; 6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one

•  URB-937; 3’-carbamoyl-6-hydroxy-[1,1’-biphenyl]-3-yl cyclohexylcarbamate

•  Viminol;1-[1-(2-chlorobenzyl)- 1H-pyrrol-2-yl]- 2-(di-sec-butylamino) ethanol

•  W-15; (E)-4-chloro-N-(1-phenethylpiperidin-2-ylidene)benzenesulfonamide

•  WIN 48,098, Pravadoline; (4-Methoxyphenyl)-[2-methy l-1-(2-(4-

morpholinyl)ethyl)indol-3- yl]methanone; OR (4-methoxyphenyl)-[2-methyl-1-(2-
morpholin-4-ylethyl)indol-3- yl]methanone

•  WIN 55,212-2; (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-

1,4-benzoxazin-6-yl]-1-napthalenylmethanone; OR [2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone

Instrument

Depressant drug definition

Source

https://www.healthvermont.gov/sites/default/files/document/reg-regulated-drugs.pdf

Retrieved

2026-11-01

Fingerprint

4d9defa81730e09c

3.4    "Depressant drug" means any drug which contains any substances, its salt, optical
       isomers, salts of its optical isomers, derivatives or analogs of substances, designated in
       Section 5.0 of this rule as habit forming because of its effect on the central nervous
       system or as having a serious potential for abuse arising out of its effect on the central
       nervous system.

Instrument

Regulated Drug Rule Sec. 7.0 - Hallucinogenic Drugs; Synthetic Cannabinoids; Tryptamines; Cannabinimimetics; Mescaline Analogs; Dissociatives (named entry: 5-MAPB)

Source

https://www.healthvermont.gov/sites/default/files/documents/pdf/REG_regulated-drugs.pdf

Retrieved

2026-07-20

Fingerprint

dd18e4f4abf49a55

7.0 Hallucinogenic Drugs; Synthetic Cannabinoids; Tryptamines; Cannabinimimetics; Mescaline Analogs; Dissociatives; Trade or Chemical Name
5-MAPB; 5-(2-Methylaminopropyl) Benzofuran

Instrument

Hallucinogenic Drugs; Synthetic Cannabinoids; Tryptamines; Cannabinimimetics; Mescaline Analogs; Dissociatives

Source

https://www.healthvermont.gov/sites/default/files/document/reg-regulated-drugs.pdf

Retrieved

2026-11-06

Fingerprint

8eb6630ae83b6269

7.0      Hallucinogenic Drugs; Synthetic Cannabinoids; Tryptamines; Cannabinimimetics;
         Mescaline Analogs; Dissociatives; Trade or Chemical Name

         •   1-(1-Phenylcyclohexyl)pyrrolidine; PCPy; Rolicyclidine

         •   1-[1-(2-Thienyl)cyclohexyl]piperidine; TCP; Tenocyclidine

         •   1-[1-(2-Thienyl)cyclohexyl]pyrrolidine; TCPy

         •   1-Piperidinocyclohexanecarbonitrile; PCC

         •   1-(4-methoxybenzoyl)-4-methylpiperazine; MEXP; Methoxypiperamide

         •   2,5-dimethoxyamphetamine; 2,5-dimethoxy-a-methylphenethylamin; 2,5 DMA

         •   2C-B; 4-bromo-2,5-dimethoxy-benzeneethanamine, monohydrochloride

         •   2C-C; 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine

         •   2C-D; 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine

         •   2C-E; 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine

         •   2C-H; 2-(2,5-Dimethoxyphenyl)ethanamine

         •   2C-I; 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine

         •   2C-N; 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine




                                                                         Effective Date:7/15/2019
                                             Page 19 of 35
•   2C-P; 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine

•   2C-T-2; 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine

•   2C-T-4; 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine

•   2C-T-7; 2,5-dimethoxy-4-(propylthio)-benzeneethanamine, monohydrochloride

•   2C-TFM-NBOMe; 2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-
    methoxyphenyl)methyl]ethanamine

•   2CBCB-NBOMe; N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-
    dimethoxybicyclo[4.2.0]octa- 1,3,5-trien-7-yl]methanamine

•   2CBFly-NBOMe; N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-
    b’]difuran-4-yl)-2-aminoethane

•   2-Fluorodeschloroketamine; 2-Fl-2'-Oxo-PCM; Fluoroketamine; 2-FDCK

•   2-MeO-ketamine; methoxyketamine; 2-MeO-2-deschloroketamine

•   2-Trifluoromethyldeschloroketamine; 2-TFMDCK; TFM-K

•   3,4,5-trimethoxy amphetamine; TMA; Mescalamphetamine

•   3,4-methylenedioxy amphetamine; MDA

•   3-HO-PCE; 3-[1-(ethylamino)cyclohexyl]phenol; 3-hydroxyethicyclidine

•   3-HO-PCP; 3-Hydroxyphencyclidine

•   3-Methoxyphencyclidine; 3-MeO-PCP; 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine

•   4-AcO-DET; 3-(2-Diethylaminoethyl)-1H-indol-4-yl acetate; 4-acetoxy-N,N-
    diethyltryptamine; Ethacetin

•   4-AcO-DMT; 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl acetate; 4-acetoxy-N,N-
    dimethyltryptamine

•   4-AcO-DPT

•   4-AcO-MET; 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl acetate




                                                              Effective Date:7/15/2019
                                   Page 20 of 35
•   4-bromo-2, 5-dimethoxyamphetamine; DOB; bromo-DMA

•   4-HO-MET; 3-(2-(ethyl(methyl)amino)ethyl)-1H-indol-4-ol

•   4-HO-MiPT; 3-(2-[Isopropyl(methyl)amino]ethyl)-1H-indol-4-ol; 4-hydroxy-MiPT

•   4-HO-MPMI; (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole

•   4-HO-MPT; 3-{2-[methyl(propyl)amino]ethyl}-1H-indol-4-ol

•   4-MeO-AET

•   4-MeO-MiPT

•   4-MeO-PCP; 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine; 4-Methoxyphencyclidine;
    Methoxydine

•   4-methoxyamphetamine; 4-methoxy-a-methylphenethylamine;
    paramethoxyamphetamine; PMA; 4-MA

•   4-methyl-2, 5-dimethoxyamphetamine; 4-methyl-2, 5-dimethoxy-a-ethylphenethylamine;
    DOM; STP

•   4-methyl-AET

•   5-APB; 5-(2-aminopropyl)benzofuran

•   5-EAPB; 5-(2-Ethylaminopropyl)Benzofuran

•   5F-APICA; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide

•   5F-AMB; 5-fluoro AMP

•   5F-ADBICA; 5-fluoro ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
    fluoropentyl)-1H-indole-3-carboxamide

•   5F-AKB48; AKB48 N-(5-fluoropentyl) analog; 5f-APINACA; APINACA 5-
    fluoropentyl analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
    carboxamide

•   5F-MN-018; 5-fluoro MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide




                                                                Effective Date:7/15/2019
                                    Page 21 of 35
•   5F-MN24; 5-fluoro NNEI; 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-
    carboxamide

•   5F-PCN; 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3-
    carboxamide

•   5F-SDB-005; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate

•   5F-THJ-2201; (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone

•   5FAB-FUBINACA

•   5FAB-PINACA; AB-PINACA 5 fluoro analog; (S)-N-(1-amino-3-methyl-1-oxobutan-
    2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide

•   5FPB22; 5-fluoro PB-22; 5-fluoro QUPIC; 1-(5-fluoropentyl)-8-quinolinyl ester-1H-
    indole-3-carboxylic acid

•   5FSDB-006; 5-fluoro SDB-006; N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide

•   5-IT; 5-(2-aminopropyl)indole

•   5-MAPB; 5-(2-Methylaminopropyl) Benzofuran

•   5-MeO-AMT; 1-(5-methoxy-1H-indol-3-yl)propan-2-amine

•   5-MeO-DALT; N-ally1-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine; 5-
    MED

•   5-MeO-DET; N,N-Diethyl-5-Methoxytryptamine; 5-methoxy-N,N-Diethyltryptamine

•   5-MeO-DiPT; 3-[2-(Diisopropylamino)ethyl]-5-methoxyindole

•   5-MeO-DMT; 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine

•   5-MeO-DPT; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine

•   5-MeO-MDA; 5-methoxy-3, 4-methylenedioxy amphetamine

•   5-MeO-MiPT; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine

•   5-MeO-MPMI; (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole




                                                               Effective Date:7/15/2019
                                    Page 22 of 35
•   5F-UR-144; (5-fluoropentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone;
    XLR11

•   6-APB; 6-(2-aminopropyl)benzofuran

•   7-hydroxymitragynine; (αE,2S,3S,7aS,12bS)-3-Ethyl-1,2,3,4,6,7,7a,12b-octahydro-7a-
    hydroxy-8-methoxy-α-(methoxymethylene)indolo[2,3-a]quinolizine-2-acetic acid methyl
    ester

•   25B-NBOMe; 2C-B NBOMe; BOM 2-CB; Cimbi-36; 2-(4-bromo-2,5-
    dimethoxyphenyl)-N- [(2-methoxyphenyl)methyl]ethanamine

•   25C-NBOMe; 2C-C-NBOMe; NBOMe-2C-C; Cimbi-82; 2-(4-chloro-2,5-
    dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

•   25I-NBF; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethanamine

•   25I-NBMD; NBMD-2C-I; Cimbi-29; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-
    methylenedioxyphenyl)methyl]ethanamine

•   25I-NBOH; 2-((2-(4-iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol

•   25I-NBOMe; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

•   A1 dodeca-2E, 4E, 8Z, 10Z – tetraenoic acid isobutyl amide

•   A2 dodeca-2E, 4E, dienoic acid idobutylamide

•   A-796,260; 1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3 tetramethylcyclopropyl)
    methanone

•   A-834,735; 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-
    tetramethylcyclopropyl)methanone

•   A-836,339; N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-
    tetramethylcyclopropane-1-carboxamide

•   AB-001; 1-pentyl-3-(1-adamantoyl) indole

•   AB-034; [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-
    tetramethylcyclopropyl)methanone




                                                                 Effective Date:7/15/2019
                                    Page 23 of 35
•   AB-CHMINACA; N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-
    1H-indazole-3-carboxamide

•   AB-FUBINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
    indazole-3-carboxamide

•   AB-FUBINACA 2-fluorobenzyl isomer

•   AB-PINACA; (s)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
    carbaxamide

•   ACEA; N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

•   ACPA; N-cyclopropyl-5Z,8Z,11Z,14Z-eicosatetraenamide

•   ADB-CHMINACA

•   ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-
    carboxamide

•   ADB-PINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
    carboxamide

•   AH-7921; 3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide

•   AKB48; N-adamantyl-1-pentylindazole-3-carboxamide; APINACA

•   AL-LAD; 6-allyl-6-nor-LSD; 6-Allyl-6-nor-lysergic acid diethylamide

•   AM-630; Iodopravadoline; [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-
    yl](4-methoxyphenyl)-methanone

•   AM-679; 1-pentyl-3-(2-iodobenzoyl)indole

•   AM-694; 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; 1-[(5-fluoropentyl)-1H-indol-3-
    yl]-(2-iodophenyl)methanone

•   AM-1220; (R)-(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)(naphthalen-1-
    yl)methanone; 1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole; 1- [(N-
    methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole

•   AM-1241; 1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole




                                                               Effective Date:7/15/2019
                                    Page 24 of 35
•   AM-1248; 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole

•   AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole

•   AM-2233; 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole

•   AM-4113

•   AMT; a-methyltryptamine

•   ASDB-FUB-187

•   BAY 38-7271; (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-
    sulfonate

•   Bromo-dragonfly; 1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine

•   Bufotenine; 3-(b-dimethylaminoethyl) 5-hydroxyindole; 3-(2-di-methylamineothyl) -5-
    indolol; N, N-dimethylserotonin; 5-hydroxy-N-dimethyltryptamine; mappine.

•   CB-13; SAB-378; CRA-13; Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone

•   CP47,497

•   CP 47,497 homologues; Known as the C6, C7, C8 or C9 homologues and also the
    dimethylhexyl, dimethylheptyl; dimethyloctyl or dimethylnonyl homologues

•   CP 50,556-1; Levonantradol; 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-
    5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; [(6S,6aR,9R, 10aR)-9-
    hydroxy-6-methyl-3-[(2R)-5-ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-
    octahydrophenanthridin-1-yl] acetate; [9-hydroxy-6-methyl-3-[5-phenylpentan-2-
    yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate

•   CP 55,940; 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-
    methyloctan-2-yl)phenol

•   cannabicyclohexanol

•   Cannabimimetic Agents

•   CUMYL- BICA

•   CUMYL-5F-PICA




                                                               Effective Date:7/15/2019
                                    Page 25 of 35
•   CUMYL-5F-PINACA

•   CUMYL-PICA

•   CUMYL-PINACA

•   CUMYL-THPINACA

•   delta-9-tetrahydrocannabinol

•   DET; Diethyltryptamine; N, N-Diethyltryptamine

•   DiPT; Diisopropyltryptamine

•   DMT; Dimethyltryptamine

•   DPT; N,N,-dipropyltryptamine

•   Dichloropane; RTI-111; O-401; methyl (1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-8-
    azabicyclo[3.2.1]octane-2-carboxylate

•   EAM-2201; JWH-210 N-(5 fluoropentyl) analog; (4-ethyl-1-naphthalenyl)[1-(5-
    fluoropentyl)-1H-indol-3-yl]-methanone

•   EG-018; naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone

•   Ethyl-ketamine; 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone

•   FDU-PB-22; naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate

•   FAB-144; (1-(5-fluoropentyl)-1H-indazol-3-yl)(2,2,3,3-
    tetramethylcyclopropyl)methanone

•   FUB-AKB48; AKB48 N-(4-fluorobenzyl) analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(4-
    fluorobenzyl)-1H-indazole-3-carboxamide

•   FUB-AMB; MMB-FUBINACA; AMB-FUBINACA; Methyl 2-(1-(4-fluorobenzyl)-1H-
    indazole-3-carboxamido)-3-methylbutanoate and its optical, positional, and geometric
    isomers, salts, and salts of isomers

•   FUB-PB22; FUB-PB-22; quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate




                                                              Effective Date:7/15/2019
                                    Page 26 of 35
•   FUBIMINA; AM2201 Benzimidazole analog; BIM-2201; FTHJ; (1-(5-fluoropentyl)-
    1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone

•   HDMP-28; Methylnaphthidate

•   HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- (2-methyloctan-2-yl)-
    6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol; [(6aR,10aR)-9-(hy droxymethyl)- 6,6-
    dimethyl-3-(2-methyl octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; 1,1-
    Dimethylheptyl-11-hydroxytetrahydrocannabinol

•   HU-211; Dexanabinol; (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-
    2-yl)- 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; (6aS, 10aS)-9-(hydroxymethyl)- 6,6-
    dimethyl- 3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol

•   HU-243; 3-dimethylheptyl-11-hydroxyhexahydrocannabinol; canbisol; nabidrox

•   HU-308; [(91R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-
    bicyclo[3.1.1]hept-3-enyl]methanol

•   HU-331; 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-
    pentyl- 2,5-cyclohexadiene-1,4-dione

•   Ibogaine; 7-Ethyl-6, 6a,7,8,9,10,12, 3-octahydro-2-methoxy-6, 9-methano-5H-pyrido (1’,
    2’: 1,2 azepine 4, 5-b) indole; tab ernanthe iboga

•   JTE-907; N-(benzol[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-
    dihydroquinoline-3-carboxamide

•   JWH-007; 1-pentyl-2-methyl-3-(1-naphthoyl)indole

•   JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone; 1-propyl-2-
    methyl-3-(1-naphthoyl)indole; (2-methyl-1-propyl-1H-indol-3-yl)-1- naphthalenyl-
    methanone

•   JWH-016; (1-butyl-2-methyl-1H-indol-3-yl)-1-naphthalenyl-methanone)

•   JWH-018; AM-678; Naphthalen-1-yl-(1-pentylindol-3-yl)methanone

•   JWH-019; napthanlen-1-yl-(1-pentylindol-3-yl)methanone; 1-hexyl-3-(1-
    naphthoyl)indole; 1-hexyl-3-(naphthoyl)indole; 1-hexyl-3-(naphthalen-1- oyl)indole

•   JWH-022; 1-naphthalenyl[1-(4-penten-1-yl)-1H-indol-3-yl]-methanone




                                                                Effective Date:7/15/2019
                                    Page 27 of 35
•   JWH-030; naphthalen-1-yl-(1-pentylpyrrol- 3-yl)methanone

•   JWH-073; naphthalen-1-yl-(1-butylindol-3-yl)methanone

•   JWH-081; 4-methoxynapthalen-1-yl-(1-pentylindol-3-yl)methanone; 1-pentyl-3-(4-
    methoxy-1-naphthoyl)indole; 4-methoxynaphthalen-1-yl-(1-pentylindole-3-yl)
    methanone; 1-pentyl-3-[1-(4-methoxynaphthoy)]indole

•   JWH-098; 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole; 4-methoxynaphthalen-
    1-yl-(1-pentyl-2-methylindol-3-yl)methanone

•   JWH-122; 1-pentyl-3-(4-methyl-1-naphthoyl)indole; (4-methyl-1-naphthalenyl)(1-
    pentyl-1H-indol-3-yl)-methanone

•   JWH-147; (1-hexyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenyl-methanone

•   JWH-164; 1-pentyl-3-(7-methoxy-1-naphthoyl)indole; 7-methoxynaphthalen-1-yl-(1-
    pentylindol-3-yl)methanone

•   JWH-167; 1-pentyl-3-(phenylacetyl)indole

•   JWH-175; 3-(napthalen-1-ylmethyl)-1-pentyl-1H-indole; 1-Pentyl-1H-indol-3-yl-(1-
    naphthyl)methane

•   JWH-176; E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane

•   JWH-184; 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane

•   JWH-199

•   JWH-200; WIN 55,225; (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-
    ylmethanone

•   JWH-201; 1-pentyl-3-(4-methocyphenylacetyl)indole; 1-pentyl-3-(4-
    methoxyphenylacetyl)indole

•   JWH-203; 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone; 1-pentyl-3-(2-
    chlorophenylacetyl)indole

•   JWH-210; 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone; 1-pentyl-3-(4-ethyl-1-
    naphthoyl)indole




                                                               Effective Date:7/15/2019
                                   Page 28 of 35
•   JWH-250; 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; 1-pentyl-3-(2-
    methoxyphenylacetyl)indole; OR 1-pentyl-3-(methoxyphenylacetyl)indole; 1-(1- pentyl-
    1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone

•   JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; 1-pentyl-3-(2-
    methylphenylacetyl)indole

•   JWH-302; 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone

•   JWH-307; (5-(2-fluorophenyl)-1-pent ylpyrrol-3-yl)-naphthalen-1-ylmethanone

•   JWH-370; [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone

•   JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole

•   L-759,633; 3-(1,1-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-methoxy-6,6,9-trimethyl-
    6H-dibenzo[b,d]pyran

•   L-759,656

•   Lysergic acid

•   Lysergic acid amide

•   Lysergic acid dimethylamide; N,N-Dimethyllysergamide

•   LSZ; Lysergic acid 2,4-dimethylazetidide; Diazedine; Lambda; LA-SS-AzLysergic
    acid diethylamide

•   MAM-2201; 4-methyl-1-naphthalenyl(1-fluoropentyl-1H-indol-3-yl)methanone

•   MiPT; N-isopropyl-N-methyltryptamine

•   MAB-CHMINACA; N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-
    1H-indazole-3-carboxamide

•   MA-CHMINICA; AMB N-methylcyclohexyl analog; AB-CHMINACA; MAB-AB-
    CHMINACA; methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-L-valinate

•   MDMB-CHMINICA; (S)-MDMB-CHMINACA; N-[[1-(cyclohexylmethyl)-1H-indazol-
    3-yl]carbonyl]-3-methyl-L-valine, methyl ester




                                                               Effective Date:7/15/2019
                                   Page 29 of 35
•   Mepirapim; JWH-018-4(methylpiperazine); (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-
    3-yl)methanone, monohydrochloride

•   Mescaline

•   Methoxetamine; MXE; 3-MeO-2-Oxo-PCE; (RS)2-(3-methoxyphenyl)-2-
    (ethylamino)cyclohexanone

•   MMB-2201; I-AMB; methyl (1-(5-fluoropentyl)-1H-indole-3-carbonyl)-L-valinate

•   MMB-CHMINACA; (2S)-methyl-2-(1-(cyclohexylmethyl)-1 H-indol-3-
    ylcarbonylamino)-3,3-dimethylbutanoate

•   MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide

•   MN-24; NNEI; N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide; AM-6527

•   Mitragynine

•   Nabilone

•   N-ethyl-3 piperidyl benzilate; JB-318

•   N-methyl-3-piperidyl benzilate; JB-336

•   NM-2201; CBL-2201

•   Parahexyl

•   Peyote

•   Psilocybin

•   Psilocin; 4-OH-DMT

•   PX-1; 5-Fluoro APP-PICA; SRF-30

•   PX-2; 5-Fluoro APP-PINACA; FU-PX

•   RCS-4; SR-19; [(4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone]; 1-pentyl-3-[(4-
    methoxy)-benzoyl]indole; 1-pentyl-3-(4-methoxybenzoyl)indole; (4- methoxyphenyl)(1-
    pentyl-1H-indol-3-yl)methanone




                                                             Effective Date:7/15/2019
                                    Page 30 of 35
•   RCS-8; SR-18; 1-(2-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(2-methyoxyphenylethanone);
    1-[2-(2-cyclohexylethyl)-1H-indol-3-yl]-2-methoxyphenylethanone; 1-(2-
    cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole

•   STS-135; N-adamantyl-1-pentylindazole-3-carboxamide

•   Salvia divinorum

•   Salvinorin A, Active ingredient of salvia plant

•   SDB-005; naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate

•   SR 144528; 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-
    1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide

•   STS-144; (1-(5-fluoropentyl)-1H-indol-3-yl)(pyridin-3-yl)methanone

•   Stramonium

•   THJ-018; JWH-018 Indazole analog; 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-
    methanone

•   THJ-2201; Fluoropentyl JWH-018 Indazole; AM2201 indazole analog; 5-Fluoro

•   Tetrahydrocannabinols (Since nomenclature of these substances is not internationally
    standardized, compounds of these structures, regardless of numeric designation of atomic
    position are covered).

•   Thiophene Analog of Phencyclidine; 1-[1-(2-thlenyl) cyclohexyl] piperidine; 2-Thyneyl
    Analog of Phencyclidine; TPCP

•   Trazodone

•   UR-144; (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone

•   URB-597; [3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate

•   URB-602; Cyclohexyl [1,1’-biphenyl]-3-ylcarbamate

•   URB-754; 6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one

•   URB-937; 3’-carbamoyl-6-hydroxy-[1,1’-biphenyl]-3-yl cyclohexylcarbamate




                                                                 Effective Date:7/15/2019
                                      Page 31 of 35
      •     Viminol; 1-[1-(2-chlorobenzyl)- 1H-pyrrol-2-yl]- 2-(di-sec-butylamino) ethanol

      •     W-15; (E)-4-chloro-N-(1-phenethylpiperidin-2-ylidene)benzenesulfonamide

      •     WIN 48,098; Pravadoline; (4-Methoxyphenyl)-[2-methy l-1-(2-(4-
            morpholinyl)ethyl)indol-3- yl]methanone; (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-
            4-ylethyl)indol-3- yl]methanone

      •     WIN 55,212-2; (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-
            de]- 1,4-benzoxazin-6-yl]-1-napthalenylmethanone; [2,3-Dihydro-5-methyl-3-(4-
            morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone

Instrument

Schedule I hallucinogenic substances (official text)

Source

https://www.healthvermont.gov/sites/default/files/documents/pdf/REG_regulated-drugs.pdf

Retrieved

2026-11-01

Fingerprint

69b793556ebd8d5b

This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes
the Vermont Board of Health to designate regulated drugs for the protection of public health
and safety.

• 4-HO-MET; 3-(2-(ethyl(methyl)amino)ethyl)-1H-indol-4-ol